Revenues (Tables)

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue by product and by geographic area

Revenues were as follows (in millions):

	Three months ended September 30,
	2020						2019
	U.S.		ROW		Total		U.S.		ROW		Total
Enbrel® (etanercept)	$	1,289	$	36	$	1,325	$	1,323	$	43	$	1,366
Prolia® (denosumab)	478		223		701		425		205		630
Neulasta® (pegfilgrastim)	484		71		555		619		92		711
Otezla® (apremilast)	439		99		538		—		—		—
XGEVA® (denosumab)	363		118		481		356		120		476
Aranesp® (darbepoetin alfa)	158		226		384		204		248		452
KYPROLIS® (carfilzomib)	173		87		260		163		103		266
Repatha® (evolocumab)	92		113		205		85		83		168
Other products	1,142		513		1,655		854		540		1,394
Total product sales(1)	$	4,618	$	1,486	6,104		$	4,029	$	1,434	5,463
Other revenues					319						274
Total revenues					$	6,423					$	5,737

	Nine months ended September 30,
	2020						2019
	U.S.		ROW		Total		U.S.		ROW		Total
ENBREL	$	3,619	$	105	$	3,724	$	3,744	$	136	$	3,880
Prolia®	1,341		673		2,014		1,273		647		1,920
Neulasta®	1,538		219		1,757		2,231		325		2,556
Otezla®	1,280		298		1,578		—		—		—
XGEVA®	1,036		361		1,397		1,091		355		1,446
Aranesp®	489		704		1,193		578		724		1,302
KYPROLIS®	527		266		793		483		295		778
Repatha®	331		303		634		259		202		461
Other products	3,164		1,652		4,816		2,503		1,477		3,980
Total product sales(1)	$	13,325	$	4,581	17,906		$	12,162	$	4,161	16,323
Other revenues					884						842
Total revenues					$	18,790					$	17,165

____________

(1)    Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2020 and 2019.